25 XP 0   0   10  
0coffee
Main menu
3rd party ad coffee SUPPORTERis ad-free.

ACAD (Acadia) Stock Analysis
Buy, Hold or Sell?

Let's analyze Acadia together

I guess you are interested in ACADIA Pharmaceuticals Inc. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

  • 📊 Fundamental Analysis (FA) – Acadia’s Financial Insights
  • 📈 Technical Analysis (TA) – Acadia’s Price Targets

I'm going to help you getting a better view of ACADIA Pharmaceuticals Inc. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

Get notifications about ACADIA Pharmaceuticals Inc

I send you an email if I find something interesting about ACADIA Pharmaceuticals Inc.

1. Quick Overview

1.1. Quick analysis of Acadia (30 sec.)










1.2. What can you expect buying and holding a share of Acadia? (30 sec.)

How much money do you get?

How much money do you get?
$0.00
When do you have the money?
1 year
How often do you get paid?
0.0%

What is your share worth?

Current worth
$4.56
Expected worth in 1 year
$6.36
How sure are you?
35.0%

+ What do you gain per year?

Total Gains per Share
$1.79
Return On Investment
8.6%

For what price can you sell your share?

Current Price per Share
$20.95
Expected price per share
$14.08 - $22.98
How sure are you?
50%
3rd party ad coffee SUPPORTERis ad-free.

2. Detailed Analysis

2.1. Valuation of Acadia (5 min.)




Live pricePrice per Share (EOD)
$20.95
Intrinsic Value Per Share
$-9.68 - $-0.38
Total Value Per Share
$-5.12 - $4.18

2.2. Growth of Acadia (5 min.)




Is Acadia growing?

Current yearPrevious yearGrowGrow %
How rich?$765.2m$413.4m$234.5m36.2%

How much money is Acadia making?

Current yearPrevious yearGrowGrow %
Making money$57.2m-$427.5k$57.6m100.7%
Net Profit Margin22.5%-0.6%--

How much money comes from the company's main activities?

2.3. Financial Health of Acadia (5 min.)




2.4. Comparing to competitors in the Biotechnology industry (5 min.)




  Industry Rankings (Biotechnology)  


Richest
#84 / 881

Most Revenue
#52 / 881

Most Profit
#36 / 881
3rd party ad coffee SUPPORTERis ad-free.

3. Summary and Key Metrics

3.1. What can you expect buying and holding a share of Acadia?

Welcome investor! Acadia's management wants to use your money to grow the business. In return you get a share of Acadia.

First you should know what it really means to hold a share of Acadia. And how you can make/lose money.

Speculation

The Price per Share of Acadia is $20.95. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Acadia.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Acadia, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is $4.56. Based on the TTM, the Book Value Change Per Share is $0.45 per quarter. Based on the YOY, the Book Value Change Per Share is $0.13 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is $0.00 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Acadia.

How much money are you going to get?

 MRQTTMYOY3Y5Y10Y
 $% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share
Usd Eps0.110.5%0.341.6%-0.10-0.5%0.010.0%-0.14-0.7%-0.26-1.2%
Usd Book Value Change Per Share0.190.9%0.452.1%0.130.6%0.160.8%0.040.2%0.070.3%
Usd Dividend Per Share0.000.0%0.000.0%0.000.0%0.000.0%0.000.0%0.000.0%
Usd Total Gains Per Share0.190.9%0.452.1%0.130.6%0.160.8%0.040.2%0.070.3%
Usd Price Per Share16.61-16.65-23.65-18.86-24.20-27.37-
Price to Earnings Ratio36.67-20.50-11.65-4.32--8.47--15.24-
Price-to-Total Gains Ratio89.54-50.87-63.38--25.39--18.08--38.42-
Price to Book Ratio3.64-4.39-9.64-6.92-7.80-10.77-
Price-to-Total Gains Ratio89.54-50.87-63.38--25.39--18.08--38.42-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share20.95
Number of shares47
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.000.00
Usd Book Value Change Per Share0.450.04
Usd Total Gains Per Share0.450.04
Gains per Quarter (47 shares)21.051.76
Gains per Year (47 shares)84.197.05
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
10847407-3
201681580144
3025324202111
4033732602818
5042141003525
6050549404232
7058957804939
8067466205646
9075874606353
10084283007060

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share4.00.00.0100.0%6.06.00.050.0%6.014.00.030.0%6.034.00.015.0%7.079.01.08.0%
Book Value Change Per Share4.00.00.0100.0%7.05.00.058.3%9.011.00.045.0%14.026.00.035.0%28.059.00.032.2%
Dividend per Share0.00.04.00.0%0.00.012.00.0%0.00.020.00.0%0.00.040.00.0%0.00.087.00.0%
Total Gains per Share4.00.00.0100.0%7.05.00.058.3%9.011.00.045.0%14.026.00.035.0%28.059.00.032.2%
3rd party ad coffee SUPPORTERis ad-free.

3.2. Key Performance Indicators

The key performance indicators of ACADIA Pharmaceuticals Inc compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-3Y+/-5 Year+/-10 Year+/-
Book Value Change Per Share--0.1860.448-59%0.134+38%0.159+17%0.037+395%0.072+159%
Book Value Per Share--4.5643.870+18%2.470+85%2.928+56%3.144+45%2.815+62%
Current Ratio--2.8792.426+19%2.367+22%2.871+0%4.443-35%7.546-62%
Debt To Asset Ratio--0.3240.388-16%0.423-23%0.381-15%0.313+4%0.210+55%
Debt To Equity Ratio--0.4800.641-25%0.737-35%0.629-24%0.485-1%0.303+58%
Dividend Per Share----0%-0%-0%-0%-0%
Enterprise Value--3099415480.0003008595810.000+3%4058963145.000-24%3337501800.000-7%4325672154.000-28%4904009336.500-37%
Eps--0.1130.342-67%-0.102+190%0.007+1426%-0.137+221%-0.256+326%
Ev To Ebitda Ratio--40.16938.071+6%68.583-41%29.244+37%5.495+631%-8.917+122%
Ev To Sales Ratio--3.1723.018+5%5.031-37%4.583-31%7.692-59%56953.661-100%
Free Cash Flow Per Share---0.4680.074-730%0.035-1425%0.009-5392%-0.083-82%-0.177-62%
Free Cash Flow To Equity Per Share---0.4570.086-634%0.072-733%0.029-1703%-0.042-91%0.031-1554%
Gross Profit Margin--1.0001.0000%0.949+5%0.994+1%1.045-4%1.061-6%
Intrinsic Value_10Y_max---0.380----------
Intrinsic Value_10Y_min---9.681----------
Intrinsic Value_1Y_max--0.025----------
Intrinsic Value_1Y_min---0.758----------
Intrinsic Value_3Y_max--0.027----------
Intrinsic Value_3Y_min---2.476----------
Intrinsic Value_5Y_max---0.029----------
Intrinsic Value_5Y_min---4.395----------
Market Cap3506233900.000+21%2784965480.0002787429560.0000%3957692895.000-30%3157568216.667-12%4049661404.000-31%4581243411.500-39%
Net Profit Margin--0.0780.225-65%-0.006+107%-0.021+127%-0.216+377%-1407.219+1810852%
Operating Margin---0.038-100%-0.0070%-0.0960%-0.2630%-1413.2440%
Operating Ratio--0.9210.769+20%1.007-9%1.032-11%1.225-25%2061.825-100%
Pb Ratio4.590+21%3.6394.388-17%9.641-62%6.920-47%7.799-53%10.775-66%
Pe Ratio46.251+21%36.66920.504+79%11.646+215%4.318+749%-8.470+123%-15.240+142%
Price Per Share20.950+21%16.61016.6480%23.648-30%18.864-12%24.196-31%27.373-39%
Price To Free Cash Flow Ratio-11.185-26%-8.86811.932-174%-1.086-88%-84.577+854%-68.311+670%-50.192+466%
Price To Total Gains Ratio112.932+21%89.53750.870+76%63.383+41%-25.392+128%-18.076+120%-38.417+143%
Quick Ratio--4.1623.334+25%3.198+30%4.035+3%6.271-34%11.676-64%
Return On Assets--0.0170.052-68%-0.005+131%-0.004+125%-0.035+311%-0.091+643%
Return On Equity--0.0250.086-71%-0.009+136%-0.005+118%-0.045+282%-0.105+524%
Total Gains Per Share--0.1860.448-59%0.134+38%0.159+17%0.037+395%0.072+159%
Usd Book Value--765237000.000647977500.000+18%413441500.000+85%490073416.667+56%526243000.000+45%471227075.000+62%
Usd Book Value Change Per Share--0.1860.448-59%0.134+38%0.159+17%0.037+395%0.072+159%
Usd Book Value Per Share--4.5643.870+18%2.470+85%2.928+56%3.144+45%2.815+62%
Usd Dividend Per Share----0%-0%-0%-0%-0%
Usd Enterprise Value--3099415480.0003008595810.000+3%4058963145.000-24%3337501800.000-7%4325672154.000-28%4904009336.500-37%
Usd Eps--0.1130.342-67%-0.102+190%0.007+1426%-0.137+221%-0.256+326%
Usd Free Cash Flow---78515000.00012400500.000-733%5916000.000-1427%1468916.667-5445%-13965050.000-82%-29682475.000-62%
Usd Free Cash Flow Per Share---0.4680.074-730%0.035-1425%0.009-5392%-0.083-82%-0.177-62%
Usd Free Cash Flow To Equity Per Share---0.4570.086-634%0.072-733%0.029-1703%-0.042-91%0.031-1554%
Usd Market Cap3506233900.000+21%2784965480.0002787429560.0000%3957692895.000-30%3157568216.667-12%4049661404.000-31%4581243411.500-39%
Usd Price Per Share20.950+21%16.61016.6480%23.648-30%18.864-12%24.196-31%27.373-39%
Usd Profit--18987000.00057220750.000-67%-427500.000+102%6769416.667+180%-19662700.000+204%-41164800.000+317%
Usd Revenue--244317000.000249070750.000-2%203451500.000+20%194193166.667+26%164080900.000+49%101921450.000+140%
Usd Total Gains Per Share--0.1860.448-59%0.134+38%0.159+17%0.037+395%0.072+159%
 EOD+5 -3MRQTTM+15 -22YOY+24 -133Y+24 -135Y+20 -1710Y+19 -18

3.3 Fundamental Score

Let's check the fundamental score of ACADIA Pharmaceuticals Inc based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-1546.251
Price to Book Ratio (EOD)Between0-14.590
Net Profit Margin (MRQ)Greater than00.078
Operating Margin (MRQ)Greater than00.000
Quick Ratio (MRQ)Greater than14.162
Current Ratio (MRQ)Greater than12.879
Debt to Asset Ratio (MRQ)Less than10.324
Debt to Equity Ratio (MRQ)Less than10.480
Return on Equity (MRQ)Greater than0.150.025
Return on Assets (MRQ)Greater than0.050.017
Total5/10 (50.0%)

3.4 Technical Score

Let's check the technical score of ACADIA Pharmaceuticals Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5044.081
Ma 20Greater thanMa 5022.051
Ma 50Greater thanMa 10019.826
Ma 100Greater thanMa 20018.514
OpenGreater thanClose21.380
Total4/5 (80.0%)

4. In-depth Analysis

4.1 About ACADIA Pharmaceuticals Inc

ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of medicines for central nervous system (CNS) disorders and rare diseases in the United States. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis; and DAYBUE, a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 for treatment of Rett Syndrome. It also develops Pimavanserin which completed Phase III clinical trial to treat the negative symptoms of schizophrenia; ACP-101, which completed phase III clinical trial for the treatment of hyperphagia in Prader-Willi syndrome; ACP-204 that completed phase II clinical trial for the treatment of Alzheimer's disease psychosis and Lewy Body Dementia with psychosis; ACP-711, which is in phase I clinical trial for the treatment of essential tremor; ACP-211 that is in phase I clinical trial for the treatment of treatment-resistant depression; ACP-2591 that is in Phase I development for Rett syndrome and Fragile X syndrome; and ACP-271, a GPR88 agonist used in evaluation of neurology and is in the IND-enabling stage. The company has a license agreement with Neuren Pharmaceuticals Limited to trofinetide for Rett syndrome and other indications; and a license and collaboration agreement with Stoke Therapeutics, Inc. to discover, develop and commercialize novel RNA-based medicines for the potential treatment of severe and rare genetic neurodevelopmental diseases of the CNS. The company was formerly known as Receptor Technologies, Inc. and changed its name ACADIA Pharmaceuticals Inc. in 1997. ACADIA Pharmaceuticals Inc. was incorporated in 1993 and is headquartered in San Diego, California.

Fundamental data was last updated by Penke on 2025-06-18 22:12:05.

4.2 In-depth Summary

4.2.1. Financial Health Summary

Profitability Details
 Compared to previous yearCompared to industry
The company is making a huge profit.
Using its assets, the company is efficient in making profit.
Using its investors money, the company is less efficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
The company is operating less efficient.
The company is efficient in keeping operating costs low.
Liquidity Details
 Compared to previous yearCompared to industry
The company is able to pay all its short-term debts.
The company is very able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is very able to pay all its debts by selling its assets.
The company is very able to pay all its debts with equity.

4.2.2. Valuation Summary

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is fair priced.
Based on the earnings, the company is fair priced.
Based on how much money comes from the company's main activities, the company is cheap.
3rd party ad coffee SUPPORTERis ad-free.

4.3 Financial Health

4.3.1. Profitability

4.3.1 Profitability
4.3.1.1. Net Profit Margin

Measures how much net profit Acadia earns for each $1 of revenue.

  • Above 10% is considered healthy but always compare Acadia to the Biotechnology industry mean.
  • A Net Profit Margin of 7.8% means that $0.08 for each $1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of ACADIA Pharmaceuticals Inc:

  • The MRQ is 7.8%. The company is making a profit. +1
  • The TTM is 22.5%. The company is making a huge profit. +2
Trends
Current periodCompared to+/- 
MRQ7.8%TTM22.5%-14.7%
TTM22.5%YOY-0.6%+23.1%
TTM22.5%5Y-21.6%+44.1%
5Y-21.6%10Y-140,721.9%+140,700.4%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ7.8%-91.7%+99.5%
TTM22.5%-139.0%+161.5%
YOY-0.6%-194.4%+193.8%
3Y-2.1%-248.5%+246.4%
5Y-21.6%-343.3%+321.7%
10Y-140,721.9%-488.9%-140,233.0%
4.3.1.2. Return on Assets

Shows how efficient Acadia is using its assets to generate profit.

  • Above 5% is considered healthy but always compare Acadia to the Biotechnology industry mean.
  • 1.7% Return on Assets means that Acadia generated $0.02 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of ACADIA Pharmaceuticals Inc:

  • The MRQ is 1.7%. Using its assets, the company is less efficient in making profit.
  • The TTM is 5.2%. Using its assets, the company is efficient in making profit. +1
Trends
Current periodCompared to+/- 
MRQ1.7%TTM5.2%-3.5%
TTM5.2%YOY-0.5%+5.7%
TTM5.2%5Y-3.5%+8.7%
5Y-3.5%10Y-9.1%+5.6%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ1.7%-11.6%+13.3%
TTM5.2%-11.7%+16.9%
YOY-0.5%-11.4%+10.9%
3Y-0.4%-11.9%+11.5%
5Y-3.5%-12.1%+8.6%
10Y-9.1%-13.8%+4.7%
4.3.1.3. Return on Equity

Shows how efficient Acadia is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare Acadia to the Biotechnology industry mean.
  • 2.5% Return on Equity means Acadia generated $0.02 for each $1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of ACADIA Pharmaceuticals Inc:

  • The MRQ is 2.5%. Using its investors money, the company is inefficient in making profit. -1
  • The TTM is 8.6%. Using its investors money, the company is less efficient in making profit.
Trends
Current periodCompared to+/- 
MRQ2.5%TTM8.6%-6.1%
TTM8.6%YOY-0.9%+9.4%
TTM8.6%5Y-4.5%+13.1%
5Y-4.5%10Y-10.5%+6.0%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ2.5%-13.5%+16.0%
TTM8.6%-15.0%+23.6%
YOY-0.9%-14.5%+13.6%
3Y-0.5%-16.9%+16.4%
5Y-4.5%-17.9%+13.4%
10Y-10.5%-19.9%+9.4%
3rd party ad coffee SUPPORTERis ad-free.

4.3.2. Operating Efficiency of ACADIA Pharmaceuticals Inc.

4.3.2. Operating Efficiency
4.3.2.1. Operating Margin

Measures how efficient Acadia is operating .

  • Measures how much profit Acadia makes for each $1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare Acadia to the Biotechnology industry mean.
  • An Operating Margin of 0.0% means the company generated $0.00  for each $1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of ACADIA Pharmaceuticals Inc:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM3.8%-3.8%
TTM3.8%YOY-0.7%+4.6%
TTM3.8%5Y-26.3%+30.1%
5Y-26.3%10Y-141,324.4%+141,298.1%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ--229.2%+229.2%
TTM3.8%-249.7%+253.5%
YOY-0.7%-208.4%+207.7%
3Y-9.6%-221.7%+212.1%
5Y-26.3%-344.1%+317.8%
10Y-141,324.4%-470.4%-140,854.0%
4.3.2.2. Operating Ratio

Measures how efficient Acadia is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Biotechnology industry mean).
  • An Operation Ratio of 0.92 means that the operating costs are $0.92 for each $1 in net sales.

Let's take a look of the Operating Ratio trends of ACADIA Pharmaceuticals Inc:

  • The MRQ is 0.921. The company is less efficient in keeping operating costs low.
  • The TTM is 0.769. The company is efficient in keeping operating costs low. +1
Trends
Current periodCompared to+/- 
MRQ0.921TTM0.769+0.152
TTM0.769YOY1.007-0.238
TTM0.7695Y1.225-0.455
5Y1.22510Y2,061.825-2,060.600
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.9212.108-1.187
TTM0.7692.680-1.911
YOY1.0073.080-2.073
3Y1.0323.621-2.589
5Y1.2254.734-3.509
10Y2,061.8256.546+2,055.279
3rd party ad coffee SUPPORTERis ad-free.

4.4.3. Liquidity of ACADIA Pharmaceuticals Inc.

4.4.3. Liquidity
4.4.3.1. Current Ratio

Measures if Acadia is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Biotechnology industry mean).
  • A Current Ratio of 2.88 means the company has $2.88 in assets for each $1 in short-term debts.

Let's take a look of the Current Ratio trends of ACADIA Pharmaceuticals Inc:

  • The MRQ is 2.879. The company is able to pay all its short-term debts. +1
  • The TTM is 2.426. The company is able to pay all its short-term debts. +1
Trends
Current periodCompared to+/- 
MRQ2.879TTM2.426+0.453
TTM2.426YOY2.367+0.059
TTM2.4265Y4.443-2.017
5Y4.44310Y7.546-3.103
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ2.8793.659-0.780
TTM2.4263.834-1.408
YOY2.3674.141-1.774
3Y2.8714.661-1.790
5Y4.4435.756-1.313
10Y7.5466.151+1.395
4.4.3.2. Quick Ratio

Measures if Acadia is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare Acadia to the Biotechnology industry mean.
  • A Quick Ratio of 4.16 means the company can pay off $4.16 for each $1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of ACADIA Pharmaceuticals Inc:

  • The MRQ is 4.162. The company is very able to pay all its short-term debts with the most liquid assets. +2
  • The TTM is 3.334. The company is very able to pay all its short-term debts with the most liquid assets. +2
Trends
Current periodCompared to+/- 
MRQ4.162TTM3.334+0.828
TTM3.334YOY3.198+0.136
TTM3.3345Y6.271-2.937
5Y6.27110Y11.676-5.404
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ4.1622.799+1.363
TTM3.3343.143+0.191
YOY3.1983.794-0.596
3Y4.0354.307-0.272
5Y6.2715.707+0.564
10Y11.6766.457+5.219
3rd party ad coffee SUPPORTERis ad-free.

4.5.4. Solvency of ACADIA Pharmaceuticals Inc.

4.5.4. Solvency
4.5.4.1. Debt to Asset Ratio

Measures how much % of Acadia assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare Acadia to Biotechnology industry mean.
  • A Debt to Asset Ratio of 0.32 means that Acadia assets are financed with 32.4% credit (debt) and the remaining percentage (100% - 32.4%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of ACADIA Pharmaceuticals Inc:

  • The MRQ is 0.324. The company is very able to pay all its debts by selling its assets. +2
  • The TTM is 0.388. The company is very able to pay all its debts by selling its assets. +2
Trends
Current periodCompared to+/- 
MRQ0.324TTM0.388-0.064
TTM0.388YOY0.423-0.035
TTM0.3885Y0.313+0.075
5Y0.31310Y0.210+0.103
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.3240.324+0.000
TTM0.3880.347+0.041
YOY0.4230.329+0.094
3Y0.3810.340+0.041
5Y0.3130.349-0.036
10Y0.2100.379-0.169
4.5.4.2. Debt to Equity Ratio

Measures if Acadia is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare Acadia to the Biotechnology industry mean.
  • A Debt to Equity ratio of 48.0% means that company has $0.48 debt for each $1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of ACADIA Pharmaceuticals Inc:

  • The MRQ is 0.480. The company is very able to pay all its debts with equity. +2
  • The TTM is 0.641. The company is very able to pay all its debts with equity. +2
Trends
Current periodCompared to+/- 
MRQ0.480TTM0.641-0.161
TTM0.641YOY0.737-0.096
TTM0.6415Y0.485+0.155
5Y0.48510Y0.303+0.182
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.4800.379+0.101
TTM0.6410.435+0.206
YOY0.7370.412+0.325
3Y0.6290.446+0.183
5Y0.4850.460+0.025
10Y0.3030.509-0.206
3rd party ad coffee SUPPORTERis ad-free.

4.6. Market Valuation

4.6.1. Earnings Per Share
4.6.2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every $1 in earnings Acadia generates.

  • Above 15 is considered overpriced but always compare Acadia to the Biotechnology industry mean.
  • A PE ratio of 36.67 means the investor is paying $36.67 for every $1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of ACADIA Pharmaceuticals Inc:

  • The EOD is 46.251. Based on the earnings, the company is overpriced. -1
  • The MRQ is 36.669. Based on the earnings, the company is overpriced. -1
  • The TTM is 20.504. Based on the earnings, the company is fair priced.
Trends
Current periodCompared to+/- 
EOD46.251MRQ36.669+9.581
MRQ36.669TTM20.504+16.166
TTM20.504YOY11.646+8.858
TTM20.5045Y-8.470+28.974
5Y-8.47010Y-15.240+6.770
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD46.251-2.282+48.533
MRQ36.669-2.062+38.731
TTM20.504-2.541+23.045
YOY11.646-3.722+15.368
3Y4.318-3.754+8.072
5Y-8.470-6.100-2.370
10Y-15.240-6.653-8.587
4.6.2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of ACADIA Pharmaceuticals Inc:

  • The EOD is -11.185. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The MRQ is -8.868. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The TTM is 11.932. Based on how much money comes from the company's main activities, the company is cheap. +2
Trends
Current periodCompared to+/- 
EOD-11.185MRQ-8.868-2.317
MRQ-8.868TTM11.932-20.800
TTM11.932YOY-1.086+13.018
TTM11.9325Y-68.311+80.243
5Y-68.31110Y-50.192-18.118
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-11.185-3.101-8.084
MRQ-8.868-2.689-6.179
TTM11.932-3.594+15.526
YOY-1.086-4.363+3.277
3Y-84.577-5.065-79.512
5Y-68.311-8.478-59.833
10Y-50.192-9.273-40.919
3rd party ad coffee SUPPORTERis ad-free.
4.6.2. Book Value per Share
4.6.2.1. Price to Book Ratio

Measures if the stock price of Acadia is to cheap or to expensive compared to its book value.

  • At or below 1 is considered healthy (always compare to Biotechnology industry mean).
  • A PB ratio of 3.64 means the investor is paying $3.64 for each $1 in book value.

Let's take a look of the Price to Book Ratio trends of ACADIA Pharmaceuticals Inc:

  • The EOD is 4.590. Based on the equity, the company is fair priced.
  • The MRQ is 3.639. Based on the equity, the company is fair priced.
  • The TTM is 4.388. Based on the equity, the company is fair priced.
Trends
Current periodCompared to+/- 
EOD4.590MRQ3.639+0.951
MRQ3.639TTM4.388-0.749
TTM4.388YOY9.641-5.252
TTM4.3885Y7.799-3.411
5Y7.79910Y10.775-2.976
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD4.5901.932+2.658
MRQ3.6391.848+1.791
TTM4.3882.119+2.269
YOY9.6412.469+7.172
3Y6.9202.526+4.394
5Y7.7993.667+4.132
10Y10.7754.351+6.424
4.6.2. Total Gains per Share

2.4. Latest News of ACADIA Pharmaceuticals Inc

Does ACADIA Pharmaceuticals Inc still have the same value as the quarterly reports suggest? Recent changes may be an indication that the value of the company is changing. Read the news from ACADIA Pharmaceuticals Inc to keep up to date. Note: the news is often already included in the price.

DateTitleRead
2025-06-20
22:02
Acadia Pharmaceuticals (ACAD) Conducts Inducement Awards to Attract and Retain Top TalentRead
2025-06-20
21:00
Catalyst Watch: Powell goes to DC, FedEx earnings, and big banks get a stress testRead
2025-06-18
09:23
Macquarie initiates Neuren Pharmaceuticals stock with outperform ratingRead
2025-06-09
22:41
Acadia gets court approval related to Nuplazid patentRead
2025-06-06
00:16
Insider Sale: Director at $ACAD Sells 14,446 SharesRead

4.7 Holders & Insider Transactions

Let's take a look at which institutions, funds and insiders are holding shares of ACADIA Pharmaceuticals Inc.

4.8.1. Institutions holding ACADIA Pharmaceuticals Inc

Institutions are holding 105.596% of the shares of ACADIA Pharmaceuticals Inc.

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2025-03-31Baker Bros Advisors LP25.61997.88124287791600
2025-03-31BlackRock Inc12.76670.007521366557863669867.846
2025-03-31Vanguard Group Inc9.0840.00461520323412555949.0022
2025-03-31RTW INVESTMENTS, LLC5.10282.16958540117-165384-1.8998
2025-03-31State Street Corp4.17870.00486993513247212854.6763
2025-03-31Morgan Stanley - Brokerage Accounts2.79640.00564680183-2616866-35.862
2025-03-31Point72 Asset Management, L.P.2.77710.176246478162417001108.3461
2025-03-31Assenagon Asset Management SA2.18880.1015366314536631450
2024-12-31D. E. Shaw & Co LP1.93680.04373241406-263551-7.5194
2025-03-31Geode Capital Management, LLC1.76530.00392954513774042.6903
2025-03-31Fred Alger Management, LLC1.6550.2622769828548992.0221
2024-12-31First Trust Advisors L.P.1.61330.0437270012557425127.0125
2025-03-31Palo Alto Investors, LLC1.59178.42582663925-84674-3.0806
2025-03-31Goldman Sachs Group Inc1.30180.00592178770-701694-24.3605
2025-03-31Jacobs Levy Equity Management, Inc.1.18150.1303197743283872873.6564
2025-03-31Citigroup Inc1.10680.0157185238318461511.0696
2025-03-31Dimensional Fund Advisors, Inc.0.98910.0068165537056853052.3104
2025-03-31American Century Companies Inc0.97560.0166163274914914841055.8058
2025-03-31TANG CAPITAL MANAGEMENT LLC0.89631.3784150000000
2025-03-31Renaissance Technologies Corp0.88250.0371147703325050020.4234
Total 80.410120.7208134576015+18652808+13.9%

4.9.2. Funds holding ACADIA Pharmaceuticals Inc

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2025-05-31iShares Core S&P Small-Cap ETF4.42220.2081740115300
2025-04-30Vanguard Total Stock Mkt Idx Inv2.39330.00344005544632621.6047
2025-04-30Vanguard Small Cap Index1.87220.03263133352138440.4438
2025-05-31iShares Russell 2000 ETF1.79250.1051300004300
2025-05-31SPDR® S&P Biotech ETF1.37711.05952304723136360.5952
2025-05-29First Trust NYSE Arca Biotech ETF1.31574.72422202061-1072-0.0487
2025-04-30Vanguard Institutional Extnd Mkt Idx Tr1.14350.0274191376322620.1183
2025-04-30Vanguard Small Cap Growth Index Inv1.04210.07631743998-7766-0.4433
2025-05-31Avantis US Small Cap Value ETF0.90680.2143151763600
2025-03-31Fidelity Small Cap Index0.71580.0823119790182140.6904
2025-05-30SPDR® Portfolio S&P 600™ Sm Cap ETF0.62330.2073104320000
2025-05-31iShares Russell 2000 Growth ETF0.62150.2031104011900
2025-05-31iShares Biotechnology ETF0.58430.422597788000
2025-03-31Eventide Healthcare & Life Sciences I0.50961.269285284500
2025-04-30Vanguard Tax-Managed Small Cap Adm0.49460.149682772500
2025-04-30JHancock Small Cap Core NAV0.47250.519479074910420215.1777
2025-05-31iShares S&P Small-Cap 600 Growth ETF0.45290.276275799900
2025-03-31Alger Weatherbie Specialized Growth A0.43323.3376725055442206.495
2025-05-31State St Russell Sm/Mid Cp® Indx SL Cl I0.42430.0372710134379005.6379
2025-04-30Fidelity Extended Market Index0.40840.02776834515310.0778
Total 22.005812.98336829331+279233+0.8%

5.3. Insider Transactions

Insiders are holding 0.681% of the shares of ACADIA Pharmaceuticals Inc.

DateOwnerTypeAmountPricePost Transaction AmountLink
2025-06-04Laura BregeSELL1444621.78
2025-05-16James KiharaSELL400022.5
2025-05-16Mark C SchneyerSELL200025
2025-05-02James KiharaSELL132714.6
2025-05-02Mark C SchneyerSELL349814.6
2025-04-08James KiharaSELL102814.82
2025-04-08Mark C SchneyerSELL270814.82
2025-03-26James KiharaSELL109517.05
2025-03-26Mark C SchneyerSELL317117.05
2025-03-05Elizabeth A GarofaloSELL491918.23
2025-02-24James KiharaSELL47519.96
2025-02-24Mark C SchneyerSELL77319.96
2024-11-19Brendan TeehanSELL1032916.81
2024-11-19James KiharaSELL407316.81
2024-11-19Mark C SchneyerSELL1025916.81
2024-08-19Brendan TeehanSELL953415.28
2024-08-19Mark C SchneyerSELL973315.28
2024-08-19Stephen DavisSELL3174715.28
3rd party ad coffee SUPPORTERis ad-free.

5. Financial Statements




5.1. Latest Balance Sheet

Balance Sheet of 2025-03-31. Currency in USD. All numbers in thousands.

Summary
Total Assets1,132,364
Total Liabilities367,127
Total Stockholder Equity765,237
 As reported
Total Liabilities 367,127
Total Stockholder Equity+ 765,237
Total Assets = 1,132,364

Assets

Total Assets1,132,364
Total Current Assets870,942
Long-term Assets261,422
Total Current Assets
Cash And Cash Equivalents 217,696
Short-term Investments 463,881
Net Receivables 113,714
Inventory 22,948
Other Current Assets 52,703
Total Current Assets  (as reported)870,942
Total Current Assets  (calculated)870,942
+/-0
Long-term Assets
Property Plant Equipment 54,112
Intangible Assets 117,060
Long-term Assets Other 90,250
Long-term Assets  (as reported)261,422
Long-term Assets  (calculated)261,422
+/-0

Liabilities & Shareholders' Equity

Total Current Liabilities302,530
Long-term Liabilities64,597
Total Stockholder Equity765,237
Total Current Liabilities
Short-term Debt 11,372
Accounts payable 18,095
Other Current Liabilities 264,015
Total Current Liabilities  (as reported)302,530
Total Current Liabilities  (calculated)293,482
+/- 9,048
Long-term Liabilities
Capital Lease Obligations Min Short Term Debt44,634
Long-term Liabilities Other 19,963
Long-term Liabilities  (as reported)64,597
Long-term Liabilities  (calculated)64,597
+/-0
Total Stockholder Equity
Common Stock16
Retained Earnings -2,185,399
Accumulated Other Comprehensive Income 437
Other Stockholders Equity 2,950,183
Total Stockholder Equity (as reported)765,237
Total Stockholder Equity (calculated)765,237
+/-0
Other
Capital Stock16
Cash and Short Term Investments 681,577
Common Stock Shares Outstanding 167,668
Liabilities and Stockholders Equity 1,132,364
Net Debt -161,690
Net Invested Capital 765,237
Net Working Capital 568,412
Property Plant and Equipment Gross 54,112
Short Long Term Debt Total 56,006



5.2. Balance Sheets Structured

Currency in USD. All numbers in thousands.

 Trend2025-03-312024-12-312024-09-302024-06-302024-03-312023-12-312023-09-302023-06-302023-03-312022-12-312022-09-302022-06-302022-03-312021-12-312021-09-302021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-302017-03-312016-12-312016-09-302016-06-302016-03-312015-12-312015-09-302015-06-302015-03-312014-12-312014-09-302014-06-302014-03-312013-12-312013-09-302013-06-302013-03-312012-12-312012-09-302012-06-302012-03-312011-12-312011-09-302011-06-302011-03-312010-12-312010-09-302010-06-302010-03-312009-12-312009-09-302009-06-302009-03-312008-12-312008-09-302008-06-302008-03-312007-12-312007-09-302007-06-302007-03-312006-12-312006-09-302006-06-302006-03-312005-12-312005-09-302005-06-302005-03-312004-12-312004-09-302004-06-302004-03-312003-12-312003-09-302003-06-302003-03-312002-12-312000-09-30
> Total Assets 
33,471
16,023
0
0
0
31,693
27,416
53,304
47,750
40,365
45,924
73,631
70,271
62,506
63,518
115,568
100,914
89,544
75,748
160,221
148,346
134,584
113,325
96,080
78,203
64,677
50,371
70,063
58,475
49,680
43,273
39,166
35,750
38,394
46,887
41,309
37,022
32,114
26,519
21,874
23,750
108,590
103,015
206,909
199,285
189,118
373,506
359,465
341,763
325,458
301,963
275,539
245,320
221,896
466,590
438,034
617,384
561,153
503,013
456,315
413,714
384,506
351,040
314,960
266,456
540,202
501,105
460,883
765,586
783,183
747,450
759,649
795,664
782,616
755,173
724,429
717,673
700,122
624,251
612,766
602,491
587,812
655,305
642,769
632,540
748,956
855,103
914,099
976,868
1,187,756
1,132,364
1,132,3641,187,756976,868914,099855,103748,956632,540642,769655,305587,812602,491612,766624,251700,122717,673724,429755,173782,616795,664759,649747,450783,183765,586460,883501,105540,202266,456314,960351,040384,506413,714456,315503,013561,153617,384438,034466,590221,896245,320275,539301,963325,458341,763359,465373,506189,118199,285206,909103,015108,59023,75021,87426,51932,11437,02241,30946,88738,39435,75039,16643,27349,68058,47570,06350,37164,67778,20396,080113,325134,584148,346160,22175,74889,544100,914115,56863,51862,50670,27173,63145,92440,36547,75053,30427,41631,69300016,02333,471
   > Total Current Assets 
0
0
0
0
0
28,272
23,690
50,258
44,905
37,818
43,653
71,398
68,000
60,125
61,121
112,661
97,804
85,783
72,365
156,893
144,951
131,253
110,170
93,107
75,535
62,382
48,287
68,214
56,804
48,473
42,267
38,318
34,992
37,849
46,548
41,015
36,763
31,949
26,387
21,775
23,685
108,548
102,985
206,761
198,675
188,360
372,820
358,854
341,065
324,618
299,899
273,393
242,847
218,989
462,352
423,897
603,490
547,897
489,753
443,745
401,972
373,477
340,014
301,096
254,116
526,106
476,406
436,940
742,330
760,250
724,421
735,735
730,213
717,616
673,984
645,730
640,917
617,823
542,223
532,519
521,552
507,937
502,850
492,628
499,170
616,125
675,296
728,916
788,284
938,318
870,942
870,942938,318788,284728,916675,296616,125499,170492,628502,850507,937521,552532,519542,223617,823640,917645,730673,984717,616730,213735,735724,421760,250742,330436,940476,406526,106254,116301,096340,014373,477401,972443,745489,753547,897603,490423,897462,352218,989242,847273,393299,899324,618341,065358,854372,820188,360198,675206,761102,985108,54823,68521,77526,38731,94936,76341,01546,54837,84934,99238,31842,26748,47356,80468,21448,28762,38275,53593,107110,170131,253144,951156,89372,36585,78397,804112,66161,12160,12568,00071,39843,65337,81844,90550,25823,69028,27200000
       Cash And Cash Equivalents 
0
4,454
0
0
0
6,308
4,368
8,157
5,693
8,302
11,236
15,812
23,353
9,796
11,264
38,420
26,229
15,480
22,315
39,631
23,462
16,987
21,005
20,285
22,213
21,171
18,840
17,984
17,322
18,122
18,067
8,811
9,656
6,849
6,829
8,020
8,317
6,889
5,558
9,208
8,016
57,899
18,436
24,247
11,803
11,707
96,455
13,698
36,369
61,854
76,424
93,212
70,799
102,138
175,220
131,774
153,679
163,620
157,383
143,789
112,616
69,418
116,328
74,182
63,897
134,758
97,557
74,432
385,474
189,680
173,059
310,441
452,352
326,028
304,487
266,956
94,640
147,435
204,920
139,833
154,842
114,846
290,895
107,941
98,193
188,657
204,745
177,134
155,149
319,589
217,696
217,696319,589155,149177,134204,745188,65798,193107,941290,895114,846154,842139,833204,920147,43594,640266,956304,487326,028452,352310,441173,059189,680385,47474,43297,557134,75863,89774,182116,32869,418112,616143,789157,383163,620153,679131,774175,220102,13870,79993,21276,42461,85436,36913,69896,45511,70711,80324,24718,43657,8998,0169,2085,5586,8898,3178,0206,8296,8499,6568,81118,06718,12217,32217,98418,84021,17122,21320,28521,00516,98723,46239,63122,31515,48026,22938,42011,2649,79623,35315,81211,2368,3025,6938,1574,3686,3080004,4540
       Short-term Investments 
0
7,985
0
0
0
20,906
18,126
40,636
37,465
27,626
30,410
53,148
39,378
33,205
32,420
55,715
68,428
67,775
47,584
114,238
117,500
109,871
85,494
69,336
50,485
38,912
27,544
48,168
37,587
28,938
22,509
25,464
22,570
30,238
38,835
32,341
27,833
24,159
20,366
12,141
15,042
50,068
83,027
181,204
184,377
174,083
272,830
340,755
301,430
260,632
221,469
177,565
169,892
112,994
282,023
280,781
435,180
365,416
312,098
273,531
254,009
271,924
181,735
182,673
150,239
338,762
316,767
307,455
298,373
507,749
478,347
348,110
192,089
305,930
273,281
289,962
445,651
373,271
241,057
296,518
281,737
301,977
111,978
267,437
247,727
250,208
265,775
323,808
410,181
436,404
463,881
463,881436,404410,181323,808265,775250,208247,727267,437111,978301,977281,737296,518241,057373,271445,651289,962273,281305,930192,089348,110478,347507,749298,373307,455316,767338,762150,239182,673181,735271,924254,009273,531312,098365,416435,180280,781282,023112,994169,892177,565221,469260,632301,430340,755272,830174,083184,377181,20483,02750,06815,04212,14120,36624,15927,83332,34138,83530,23822,57025,46422,50928,93837,58748,16827,54438,91250,48569,33685,494109,871117,500114,23847,58467,77568,42855,71532,42033,20539,37853,14830,41027,62637,46540,63618,12620,9060007,9850
       Net Receivables 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
2,930
1,934
0
0
0
0
0
0
0
0
0
0
0
0
0
1,642
1,320
1,139
964
746
1,508
206
1,638
783
1,633
5,224
7,140
9,519
12,378
15,254
18,430
23,348
26,682
20,682
27,789
33,770
32,722
32,269
37,874
44,571
46,128
47,784
50,282
57,390
51,820
61,668
65,344
63,482
68,889
56,136
63,080
70,250
84,156
94,532
102,350
100,079
110,393
98,209
104,695
113,714
113,714104,69598,209110,393100,079102,35094,53284,15670,25063,08056,13668,88963,48265,34461,66851,82057,39050,28247,78446,12844,57137,87432,26932,72233,77027,78920,68226,68223,34818,43015,25412,3789,5197,1405,2241,6337831,6382061,5087469641,1391,3201,64200000000000001,9342,9300000000000000000000000000000000
       Inventory 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
2,867
4,301
4,175
3,881
6,003
5,536
5,248
5,583
4,737
4,347
4,070
4,570
3,824
4,846
6,341
6,318
6,210
7,979
9,682
10,311
10,786
14,336
7,881
7,009
6,327
5,844
6,636
6,095
9,199
20,768
35,819
61,936
71,525
61,041
21,949
22,948
22,94821,94961,04171,52561,93635,81920,7689,1996,0956,6365,8446,3277,0097,88114,33610,78610,3119,6827,9796,2106,3186,3414,8463,8244,5704,0704,3474,7375,5835,2485,5366,0033,8814,1754,3012,8670000000000000000000000000000000000000000000000000000000
   > Long-term Assets 
0
0
0
0
0
3,421
3,726
3,045
2,844
2,547
2,272
2,232
2,271
2,381
2,397
2,907
3,110
3,761
3,383
3,328
3,395
3,331
3,155
2,973
2,668
2,295
2,084
1,849
1,671
1,207
1,006
848
758
545
339
294
259
165
132
99
65
42
30
148
610
758
686
611
698
840
2,064
2,146
2,473
2,907
4,238
14,137
13,894
13,256
13,260
12,570
11,742
11,029
11,026
13,864
12,340
14,096
24,699
23,943
23,256
22,933
23,029
23,914
65,451
65,000
81,189
78,699
76,756
82,299
82,028
80,247
80,939
79,875
152,455
150,141
133,370
132,831
179,807
185,183
188,584
249,438
261,422
261,422249,438188,584185,183179,807132,831133,370150,141152,45579,87580,93980,24782,02882,29976,75678,69981,18965,00065,45123,91423,02922,93323,25623,94324,69914,09612,34013,86411,02611,02911,74212,57013,26013,25613,89414,1374,2382,9072,4732,1462,064840698611686758610148304265991321652592943395457588481,0061,2071,6711,8492,0842,2952,6682,9733,1553,3313,3953,3283,3833,7613,1102,9072,3972,3812,2712,2322,2722,5472,8443,0453,7263,42100000
       Property Plant Equipment 
2,880
2,419
0
0
0
3,117
2,801
2,761
2,549
2,547
2,272
2,232
2,249
2,283
2,299
2,811
3,014
3,505
3,287
3,141
3,095
3,048
2,919
2,712
2,420
2,103
1,846
1,657
1,498
1,062
870
698
622
426
244
208
181
151
121
92
63
42
30
92
490
579
543
500
520
553
1,786
1,813
2,068
2,203
2,623
2,897
3,159
3,081
3,471
3,296
2,991
2,662
2,709
2,760
3,372
3,309
14,655
14,245
13,208
12,704
13,702
14,567
56,659
56,444
72,868
70,568
68,613
66,315
65,717
64,433
63,134
61,594
59,746
57,575
55,642
56,467
58,650
56,534
48,241
50,786
54,112
54,11250,78648,24156,53458,65056,46755,64257,57559,74661,59463,13464,43365,71766,31568,61370,56872,86856,44456,65914,56713,70212,70413,20814,24514,6553,3093,3722,7602,7092,6622,9913,2963,4713,0813,1592,8972,6232,2032,0681,8131,78655352050054357949092304263921211511812082444266226988701,0621,4981,6571,8462,1032,4202,7122,9193,0483,0953,1413,2873,5053,0142,8112,2992,2832,2492,2322,2722,5472,5492,7612,8013,1170002,4192,880
       Goodwill 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000
       Long Term Investments 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
2,900
1,182
1,300
1,100
1,100
1,800
2,300
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0000000000000000000002,3001,8001,1001,1001,3001,1822,900000000000000000000000000000000000000000000000000000000000000000
       Intangible Assets 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
7,754
7,385
7,015
6,646
6,277
5,907
5,538
5,169
4,800
4,431
4,062
3,692
3,323
2,954
2,585
2,215
1,846
1,477
1,108
738
369
0
0
0
0
0
0
69,583
68,219
66,855
65,490
110,204
107,859
105,515
119,782
117,060
117,060119,782105,515107,859110,20465,49066,85568,21969,5830000003697381,1081,4771,8462,2152,5852,9543,3233,6924,0624,4314,8005,1695,5385,9076,2776,6467,0157,3857,7540000000000000000000000000000000000000000000000000000000
       Long-term Assets Other 
0
0
0
0
0
304
925
285
295
0
0
0
22
98
98
96
96
256
96
187
300
283
236
261
248
192
238
192
173
145
136
150
136
119
95
86
78
14
11
7
2
-42
0
56
120
179
143
111
178
-97,917
278
333
405
704
1,615
3,486
3,350
3,160
3,143
2,997
2,844
2,829
3,148
3,404
3,355
5,425
5,252
5,275
5,294
5,344
6,312
6,301
6,315
6,148
1,813
1,992
2,373
6,614
10,541
10,044
17,805
5,311
23,126
24,347
10,873
5,104
10,953
15,020
34,828
78,870
90,250
90,25078,87034,82815,02010,9535,10410,87324,34723,1265,31117,80510,04410,5416,6142,3731,9921,8136,1486,3156,3016,3125,3445,2945,2755,2525,4253,3553,4043,1482,8292,8442,9973,1433,1603,3503,4861,615704405333278-97,917178111143179120560-4227111478869511913615013614517319223819224826123628330018796256969698982200029528592530400000
> Total Liabilities 
7,600
9,611
0
0
0
84,364
85,832
10,512
10,390
9,685
13,554
12,481
21,074
23,135
23,659
27,022
22,513
22,385
18,953
15,951
18,612
20,650
14,658
14,876
11,961
11,685
11,985
43,650
39,508
37,566
36,175
36,010
35,924
8,706
8,779
8,488
8,878
8,752
8,934
9,166
6,086
23,606
23,353
25,434
18,531
6,987
8,046
9,357
11,274
15,969
16,869
19,718
17,974
22,134
21,339
29,219
39,326
42,742
45,489
41,175
36,388
49,221
46,871
50,240
43,016
61,123
82,749
71,969
76,297
84,048
109,068
96,636
140,797
155,607
173,567
159,591
150,718
159,228
179,454
177,918
176,805
187,399
281,047
246,976
270,366
317,201
391,059
397,399
399,688
454,963
367,127
367,127454,963399,688397,399391,059317,201270,366246,976281,047187,399176,805177,918179,454159,228150,718159,591173,567155,607140,79796,636109,06884,04876,29771,96982,74961,12343,01650,24046,87149,22136,38841,17545,48942,74239,32629,21921,33922,13417,97419,71816,86915,96911,2749,3578,0466,98718,53125,43423,35323,6066,0869,1668,9348,7528,8788,4888,7798,70635,92436,01036,17537,56639,50843,65011,98511,68511,96114,87614,65820,65018,61215,95118,95322,38522,51327,02223,65923,13521,07412,48113,5549,68510,39010,51285,83284,3640009,6117,600
   > Total Current Liabilities 
2,968
6,153
0
0
0
8,226
10,441
9,565
9,364
8,641
11,693
11,078
19,689
21,701
21,743
25,306
20,767
20,534
17,272
14,326
17,155
19,287
13,472
13,889
11,202
11,051
11,436
20,936
15,248
14,707
13,550
12,984
13,168
5,959
6,139
5,947
6,409
6,165
6,433
6,760
6,086
5,948
5,695
7,776
7,870
6,979
8,033
9,339
11,253
15,834
16,651
19,378
17,735
21,902
21,122
29,022
39,149
42,585
45,265
40,913
36,143
49,030
46,089
49,214
41,807
59,565
74,983
63,814
67,744
74,826
99,741
86,422
91,856
105,967
109,373
95,328
88,218
96,068
119,603
117,681
116,570
125,630
224,301
187,942
209,603
254,254
330,597
337,851
343,945
394,870
302,530
302,530394,870343,945337,851330,597254,254209,603187,942224,301125,630116,570117,681119,60396,06888,21895,328109,373105,96791,85686,42299,74174,82667,74463,81474,98359,56541,80749,21446,08949,03036,14340,91345,26542,58539,14929,02221,12221,90217,73519,37816,65115,83411,2539,3398,0336,9797,8707,7765,6955,9486,0866,7606,4336,1656,4095,9476,1395,95913,16812,98413,55014,70715,24820,93611,43611,05111,20213,88913,47219,28717,15514,32617,27220,53420,76725,30621,74321,70119,68911,07811,6938,6419,3649,56510,4418,2260006,1532,968
       Short-term Debt 
0
0
0
0
0
3,242
3,167
2,604
2,059
1,486
845
855
926
890
805
826
902
996
1,039
1,047
1,017
978
934
882
815
795
685
560
450
365
291
161
111
78
44
40
37
32
22
13
3
0
0
0
0
0
0
0
0
2,822
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
4,468
4,412
3,889
3,434
2,909
2,653
3,857
5,087
6,082
7,521
8,150
8,304
8,944
9,024
9,231
9,305
9,173
9,058
9,031
9,405
10,453
10,470
8,949
9,958
11,372
11,3729,9588,94910,47010,4539,4059,0319,0589,1739,3059,2319,0248,9448,3048,1507,5216,0825,0873,8572,6532,9093,4343,8894,4124,46800000000000000002,822000000003132232374044781111612913654505606857958158829349781,0171,0471,0399969028268058909268558451,4862,0592,6043,1673,24200000
       Short Long Term Debt 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
4,468
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0000000000000000000000004,468000000000000000000000000000000000000000000000000000000000000000000
       Accounts payable 
379
1,121
0
0
0
1,533
2,530
1,985
2,450
2,153
1,357
2,317
1,730
2,073
733
3,419
3,206
3,387
3,058
2,273
2,950
2,590
2,047
3,217
2,450
2,283
4,185
3,981
2,554
2,947
2,122
2,300
2,617
1,972
1,380
1,139
1,262
1,960
1,035
757
1,131
1,375
1,396
1,177
1,120
372
1,562
1,104
1,110
2,016
2,518
2,916
2,204
1,672
1,307
1,024
2,828
3,912
2,166
3,588
2,962
8,786
2,996
3,333
2,955
3,167
3,275
4,650
3,444
7,222
6,623
6,466
3,471
8,493
8,849
9,065
7,722
6,876
10,768
11,854
10,008
12,746
17,422
18,811
12,310
17,543
19,332
19,882
19,081
16,192
18,095
18,09516,19219,08119,88219,33217,54312,31018,81117,42212,74610,00811,85410,7686,8767,7229,0658,8498,4933,4716,4666,6237,2223,4444,6503,2753,1672,9553,3332,9968,7862,9623,5882,1663,9122,8281,0241,3071,6722,2042,9162,5182,0161,1101,1041,5623721,1201,1771,3961,3751,1317571,0351,9601,2621,1391,3801,9722,6172,3002,1222,9472,5543,9814,1852,2832,4503,2172,0472,5902,9502,2733,0583,3873,2063,4197332,0731,7302,3171,3572,1532,4501,9852,5301,5330001,121379
       Other Current Liabilities 
1,260
2,057
0
0
0
2,131
2,423
2,990
3,201
3,682
3,657
3,405
12,865
15,292
16,164
17,145
13,868
13,485
10,050
8,510
11,524
15,012
10,321
9,620
7,767
7,535
6,474
7,270
6,340
5,358
5,048
4,128
3,760
3,219
4,253
4,015
4,402
3,504
4,693
5,225
4,686
4,139
4,159
6,488
6,670
6,552
6,429
8,206
10,128
13,818
14,133
16,462
15,531
20,230
19,815
27,485
34,445
36,029
38,967
37,325
33,181
40,244
43,093
45,881
38,852
56,398
67,240
54,752
60,411
64,170
90,209
77,303
84,528
92,387
94,442
78,742
72,346
80,888
99,891
96,803
97,331
103,202
197,706
160,073
179,810
225,742
293,221
299,043
315,915
356,704
264,015
264,015356,704315,915299,043293,221225,742179,810160,073197,706103,20297,33196,80399,89180,88872,34678,74294,44292,38784,52877,30390,20964,17060,41154,75267,24056,39838,85245,88143,09340,24433,18137,32538,96736,02934,44527,48519,81520,23015,53116,46214,13313,81810,1288,2066,4296,5526,6706,4884,1594,1394,6865,2254,6933,5044,4024,0154,2533,2193,7604,1285,0485,3586,3407,2706,4747,5357,7679,62010,32115,01211,5248,51010,05013,48513,86817,14516,16415,29212,8653,4053,6573,6823,2012,9902,4232,1310002,0571,260
   > Long-term Liabilities 
0
0
0
0
0
76,138
75,391
946
1,026
1,044
1,861
1,403
1,385
1,433
1,916
1,716
1,746
1,851
1,681
1,625
1,457
1,363
1,186
987
759
634
549
22,714
24,260
22,859
22,625
23,026
22,756
2,747
2,640
2,541
2,469
2,587
2,501
2,406
0
17,658
17,658
17,658
10,661
8
13
18
21
135
218
340
239
232
217
197
177
157
224
262
245
191
782
1,026
1,209
1,558
7,766
8,155
8,553
9,222
9,327
10,214
48,941
49,640
64,194
64,263
62,500
63,160
59,851
60,237
60,235
61,769
56,746
59,034
60,763
62,947
60,462
59,548
55,743
60,093
64,597
64,59760,09355,74359,54860,46262,94760,76359,03456,74661,76960,23560,23759,85163,16062,50064,26364,19449,64048,94110,2149,3279,2228,5538,1557,7661,5581,2091,026782191245262224157177197217232239340218135211813810,66117,65817,65817,65802,4062,5012,5872,4692,5412,6402,74722,75623,02622,62522,85924,26022,7145496347599871,1861,3631,4571,6251,6811,8511,7461,7161,9161,4331,3851,4031,8611,0441,02694675,39176,13800000
       Warrants
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
17,658
17,658
17,658
10,659
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
000000000000000000000000000000000000000000000010,65917,65817,65817,65800000000000000000000000000000000000000000
       Other Liabilities 
0
0
0
0
0
0
0
0
0
0
1,007
584
458
542
1,183
883
602
472
178
186
202
207
247
257
199
204
225
22,486
24,106
22,761
22,560
22,975
22,715
2,715
2,617
2,528
2,467
2,587
2,501
2,406
0
0
0
0
2
8
13
18
21
135
218
340
239
232
217
197
177
157
224
262
245
191
782
1,026
1,209
1,558
1,012
1,413
2,174
2,861
3,237
4,545
3,598
5,180
3,613
5,129
4,823
7,034
4,373
5,544
6,466
9,074
5,305
0
12,660
0
0
0
0
0
0
00000012,66005,3059,0746,4665,5444,3737,0344,8235,1293,6135,1803,5984,5453,2372,8612,1741,4131,0121,5581,2091,0267821912452622241571771972172322393402181352118138200002,4062,5012,5872,4672,5282,6172,71522,71522,97522,56022,76124,10622,4862252041992572472072021861784726028831,1835424585841,0070000000000
       Deferred Long Term Liability 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
2,481
2,441
2,587
2,501
2,406
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0000000000000000000000000000000000000000000000000002,4062,5012,5872,4412,48100000000000000000000000000000000000
> Total Stockholder Equity
25,871
6,412
0
0
0
-52,671
-58,415
42,792
37,359
30,680
32,371
61,150
49,197
39,371
39,859
88,546
78,401
67,159
56,795
144,270
129,734
113,934
98,667
81,204
66,242
52,992
38,386
26,413
18,967
12,114
7,098
3,156
-174
29,688
38,108
32,821
28,144
23,362
17,585
12,708
17,664
84,984
79,662
181,475
180,754
182,131
365,460
350,108
330,489
309,489
285,094
255,821
227,346
199,762
445,251
408,815
578,058
518,411
457,524
415,140
377,326
335,285
304,169
264,720
223,440
479,079
418,356
388,914
689,289
699,135
638,382
663,013
654,867
627,009
581,606
564,838
566,955
540,894
444,797
434,848
425,686
400,413
374,258
395,793
362,174
431,755
464,044
516,700
577,180
732,793
765,237
765,237732,793577,180516,700464,044431,755362,174395,793374,258400,413425,686434,848444,797540,894566,955564,838581,606627,009654,867663,013638,382699,135689,289388,914418,356479,079223,440264,720304,169335,285377,326415,140457,524518,411578,058408,815445,251199,762227,346255,821285,094309,489330,489350,108365,460182,131180,754181,47579,66284,98417,66412,70817,58523,36228,14432,82138,10829,688-1743,1567,09812,11418,96726,41338,38652,99266,24281,20498,667113,934129,734144,27056,79567,15978,40188,54639,85939,37149,19761,15032,37130,68037,35942,792-58,415-52,6710006,41225,871
   Common Stock
0
0
0
0
0
0
0
2
2
2
2
2
2
2
2
3
3
3
3
4
4
4
4
4
4
4
4
4
4
4
4
4
4
4
5
5
5
5
5
5
6
7
7
8
9
9
10
10
10
10
10
10
10
10
11
11
12
12
12
12
12
12
12
12
12
14
14
14
15
15
15
15
16
16
16
16
16
16
16
16
16
16
16
16
16
16
16
16
16
16
16
1616161616161616161616161616161616161615151515141414121212121212121212111110101010101010109987765555554444444444444443333222222220000000
   Retained Earnings Total Equity00000000-2,412,5720-2,327,826-2,300,643-2,266,632-2,153,576-2,110,482-2,096,025-2,052,154-1,985,706-1,918,946-1,834,286-1,792,145-1,704,122-1,651,086-1,609,108-1,554,167-1,468,863-1,403,371-1,341,233-1,277,967-1,223,671-1,154,801-1,089,553-1,022,112-933,979-855,283-783,670-712,348-662,586-616,802-577,896-538,518-498,143-469,777-444,991-423,496-405,668-393,619-382,924-373,843-367,720-360,910-358,508-353,089-346,871-341,571-336,49500000000000000000000000000000000000
   Accumulated Other Comprehensive Income 
0
0
0
0
0
-2,499
-3,660
-3,102
-2,467
-1,793
-1,445
-1,188
-936
-639
-168
42
194
176
187
297
433
493
668
307
148
273
92
100
197
483
469
401
528
512
537
10
6
9
6
3
4
4
15
-26
84
48
0
94
77
-9
4
11
45
11
316
206
533
106
94
-97
-73
-399
-699
-500
-314
-372
207
554
420
297
1,525
1,480
509
36
34
38
-1
-192
-612
-843
-1,365
-975
-220
-535
-319
24
-229
-339
858
292
437
437292858-339-22924-319-535-220-975-1,365-843-612-192-13834365091,4801,525297420554207-372-314-500-699-399-73-97941065332063161145114-9779404884-2615443696105375125284014694831971009227314830766849343329718717619442-168-639-936-1,188-1,445-1,793-2,467-3,102-3,660-2,49900000
   Capital Surplus 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
369,301
369,704
370,219
370,663
371,208
378,564
452,693
453,483
564,417
574,280
587,742
788,946
794,995
800,179
807,631
823,598
833,696
844,093
862,327
1,157,272
1,192,268
1,432,796
1,452,272
1,479,530
1,504,778
1,532,188
1,559,343
1,582,823
1,606,441
1,627,113
1,948,300
1,972,302
1,997,454
2,339,940
2,402,945
2,428,987
2,495,804
2,573,288
2,612,663
2,633,710
2,660,809
2,677,422
2,694,646
2,712,025
2,736,318
2,754,861
0
2,787,034
0
0
0
0
0
0
0
0
000000002,787,03402,754,8612,736,3182,712,0252,694,6462,677,4222,660,8092,633,7102,612,6632,573,2882,495,8042,428,9872,402,9452,339,9401,997,4541,972,3021,948,3001,627,1131,606,4411,582,8231,559,3431,532,1881,504,7781,479,5301,452,2721,432,7961,192,2681,157,272862,327844,093833,696823,598807,631800,179794,995788,946587,742574,280564,417453,483452,693378,564371,208370,663370,219369,704369,30100000000000000000000000000000000000
   Treasury Stock0000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000
   Other Stockholders Equity 
0
0
0
0
0
18,194
20,091
126,626
126,773
126,754
133,686
168,244
168,345
168,426
177,910
238,254
239,220
240,446
242,625
340,742
342,115
343,293
344,231
345,416
346,227
346,815
347,391
348,137
349,322
350,872
351,357
351,771
352,541
353,278
367,505
369,301
369,704
370,219
370,663
371,208
378,564
452,693
453,483
564,417
574,280
587,742
788,946
794,995
800,179
807,631
823,598
833,696
844,093
862,327
1,157,272
1,192,268
1,432,796
1,452,272
1,479,530
1,504,778
1,532,188
1,559,343
1,582,823
1,606,441
1,627,113
1,948,300
1,972,302
1,997,454
2,339,940
2,402,945
2,428,987
2,495,804
2,573,288
2,612,663
2,633,710
2,660,809
2,677,422
2,694,646
2,712,025
2,736,318
2,754,861
2,770,923
2,787,034
2,807,770
2,839,111
2,862,552
2,878,539
2,897,916
2,924,434
2,936,871
2,950,183
2,950,1832,936,8712,924,4342,897,9162,878,5392,862,5522,839,1112,807,7702,787,0342,770,9232,754,8612,736,3182,712,0252,694,6462,677,4222,660,8092,633,7102,612,6632,573,2882,495,8042,428,9872,402,9452,339,9401,997,4541,972,3021,948,3001,627,1131,606,4411,582,8231,559,3431,532,1881,504,7781,479,5301,452,2721,432,7961,192,2681,157,272862,327844,093833,696823,598807,631800,179794,995788,946587,742574,280564,417453,483452,693378,564371,208370,663370,219369,704369,301367,505353,278352,541351,771351,357350,872349,322348,137347,391346,815346,227345,416344,231343,293342,115340,742242,625240,446239,220238,254177,910168,426168,345168,244133,686126,754126,773126,62620,09118,19400000



5.3. Balance Sheets

Currency in USD. All numbers in thousands.




5.4. Cash Flows

Currency in USD. All numbers in thousands.




5.5. Income Statements

Currency in USD. All numbers in thousands.


5.6. Latest Income Statement

Income Statement (annual), 2024-12-31. Currency in USD. All numbers in thousands.

Gross Profit (+$)
totalRevenue957,797
Cost of Revenue-81,841
Gross Profit875,956875,956
 
Operating Income (+$)
Gross Profit875,956
Operating Expense-645,162
Operating Income230,794230,794
 
Operating Expense (+$)
Research Development303,249
Selling General Administrative488,428
Selling And Marketing Expenses0
Operating Expense645,162791,677
 
Net Interest Income (+$)
Interest Income25,458
Interest Expense-0
Other Finance Cost-0
Net Interest Income25,458
 
Pretax Income (+$)
Operating Income230,794
Net Interest Income25,458
Other Non-Operating Income Expenses0
Income Before Tax (EBT)258,075203,513
EBIT - interestExpense = 84,279
258,075
226,451
Interest Expense0
Earnings Before Interest and Taxes (EBIT)84,279258,075
Earnings Before Interest and Taxes (EBITDA)100,162
 
After tax Income (+$)
Income Before Tax258,075
Tax Provision-31,624
Net Income From Continuing Ops226,451226,451
Net Income226,451
Net Income Applicable To Common Shares0
 
Non-recurring Events
Discontinued Operations0
Extraordinary Items0
Effect of Accounting Charges0
Other Items0
Non Recurring0
Other Operating Expenses873,518
Total Other Income/Expenses Net27,281-25,458
 

Technical Analysis of Acadia
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of Acadia. The general trend of Acadia is BULLISH with 71.4% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine Acadia's overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator zone transitionsBullish trend (71.4%) Bearish trend (-71.4%)
Overbought to neutralBullish pullback=Bearish reversal
Upper to lower neutralBullish correction=Bearish continuation
Nuetral to oversoldOversold=Oversold
Oversold to neutralBullish reversal=Bearish correction
Lower to upper neutralBullish continuation=Bearish pullback
Nuetral to overboughtOverbought=Overbought

1. Acadia Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

Support is a price level at which demand for an asset is strong enough to prevent the price from falling further.
Resistance is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.


Score

Let's take a look at the Support & Resistance of ACADIA Pharmaceuticals Inc.

The long score for the Support & Resistance is 1/1.
The longshort score for the Support & Resistance is 1/(-1 +1).

  • Around support: The price is currently trading around a support level. This can be considered as a potential entry level. +1

The bullish price targets are: 21.04 < 21.35 < 22.98.

The bearish price targets are: 20.68 > 14.18 > 14.08.

Know someone who trades $ACAD? Share this with them.👇

ACADIA Pharmaceuticals Inc Daily Support & Resistance Chart
3rd party ad coffee SUPPORTERis ad-free.

2. Trend Indicators

2.1 Moving Averages

Shows the moving average of the selected period.

  • Moving averages are lagging trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of ACADIA Pharmaceuticals Inc. The current mas is .

The long score for the Moving Averages is 12/14.
The longshort score for the Moving Averages is 10/(-14 +14).

  • MA 20 trending down: The MA 20 is trending down. -1
  • Close < MA 20: The price is below the MA 20. -1
  • MA 20 > MA 50: The MA 20 is higher than the MA 50. +1
  • MA 20 > MA 100: The MA 20 is higher than the MA 100. +1
  • MA 20 > MA 200: The MA 20 is higher than the MA 200. +1
  • MA 50 trending up: The MA 50 is trending up. +1
  • Close > MA 50: The price is above the MA 50. +1
  • MA 50 > MA 100: The MA 50 is higher than the MA 100. +1
  • MA 50 > MA 200: The MA 50 is higher than the MA 200. +1
  • MA 100 trending up: The MA 100 is trending up. +1
  • Close > MA 100: The price is above the MA 100. +1
  • MA 100 > MA 200: The MA 100 is higher than the MA 200. +1
  • MA 200 trending up: The MA 200 is trending up. +1
  • Close > MA 200: The price is above the MA 200. +1

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200
MA 2020
MA 5050-
MA 100100--
MA 200200---

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

ACADIA Pharmaceuticals Inc Daily Moving Averages Chart
2.2 Moving Average Convergence/Divergence (MACD)

Shows the momentum of the selected period based on two moving averages.

  • MACD is a lagging momentum indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of ACADIA Pharmaceuticals Inc. The current macd is 0.29576307.

The long score for the Moving Average Convergence/Divergence (MACD) is 1/4.
The longshort score for the Moving Average Convergence/Divergence (MACD) is -2/(-4 +4).

  • MACD line < signal line: The MACD line is below the signal line, which indicates a bearish signal in the market. This means that the negative momentum is currently stronger than the average momentum, suggesting that sellers are more active than buyers, and there's a higher probability of the Acadia price going down in the near term. -2
  • MACD > 0: The MACD is above the zero line (centerline), it indicates a bullish signal for Acadia. This means that the short-term moving average is higher than the long-term moving average, signaling positive momentum and suggesting a higher likelihood of the Acadia price continuing to rise in the near future. It indicates that buyers are gaining control, and there is optimism in the market, leading to potential price increases. +1
  • Trending down: The MACD line is trending down. This indicates that the short-term moving average is falling faster than the long-term moving average, suggesting negative momentum in the market. This signals that sellers are becoming more active and insecure, leading to potential price decreases as traders anticipate further losses and are willing to sell at lower prices. -1
ACADIA Pharmaceuticals Inc Daily Moving Average Convergence/Divergence (MACD) ChartACADIA Pharmaceuticals Inc Daily Moving Average Convergence/Divergence (MACD) Chart
2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.


Score

Let's take a look at the Directional Movement Index (DMI) of ACADIA Pharmaceuticals Inc. The current adx is 36.73.

The long score for the Directional Movement Index (DMI) is 3/7.
The longshort score for the Directional Movement Index (DMI) is 3/(-7 +7).

  • PLUS_ID > MINUS_DI: The +DI line is above the -DI line. This indicates a bullish signal in the market, as the positive directional movement is currently stronger than the negative directional movement, showing that buyers have the upper hand. Market psychology suggests that traders are optimistic, expecting further price increases, and are more willing to buy Acadia shares, leading to potential upward momentum in its price. +1
  • PLUS_ID > MINUS_DI && ADX > 25 && ADX trending down: The ADX is above 25 and indicates a strong bullish trend. The ADX is declining, the bullish trend is weakening. Could be a potential reversal to the downside. +2
ACADIA Pharmaceuticals Inc Daily Directional Movement Index (DMI) Chart
2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

  • Parabolic SAR (stop and reverse) is a lagging trend indicator.
  • Shows the current trend.
  • Shows potential entry signals.
  • Shows  potential exit signals.
  • Can be used to place trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of ACADIA Pharmaceuticals Inc. The current sar is 23.16.

The long score for the Parabolic SAR is 0/1.
The longshort score for the Parabolic SAR is -1/(-1 +1).

  • Close < SAR: The price is below the SAR. It's generally considered a bearish signal. -1
ACADIA Pharmaceuticals Inc Daily Parabolic SAR Chart
3rd party ad coffee SUPPORTERis ad-free.

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

  • Leading momentum indicator, meaning the signals are instant.
  • Ranges between 0 and 100.
  • Above 70 is considered overbought.
  • Below 30 is considered oversold.
  • Above or below 50 can also be used to determine price trend or support and resistance.
  • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
  • Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of ACADIA Pharmaceuticals Inc. The current rsi is 44.08. The current phase is Correction in bull market.

The long score for the Relative Strength Index (RSI) is 0/13.
The longshort score for the Relative Strength Index (RSI) is -4/(-13 +13).

  • Correction in bull market: Moderate price decline, potential pause in the uptrend. Reassess the market, wait for signs of stabilization.
  • Trending down: The RSI is trending down. -1
ACADIA Pharmaceuticals Inc Daily Relative Strength Index (RSI) ChartACADIA Pharmaceuticals Inc Daily Relative Strength Index (RSI) Chart
3.2 Stochastic Oscillator

Compares a certain price to multiple prices ranging over time.

  • Leading momentum indicator, meaning the signals are instant.
  • Used to determine overbought and oversold areas much like the RSI.
  • Ranges between 0 and 100.
  • Above 80 is considered overbought.
  • Below 20 is considered oversold.
  • Consists of two lines named K and D.
  • K compares the highest high and lowest low on the selected price range.
  • The D line is a moving average of the K line.
  • Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of ACADIA Pharmaceuticals Inc. The current phase is Oversold in bull market.

The long score for the Stochastic Oscillator is 1/6.
The longshort score for the Stochastic Oscillator is -4/(-6 +6).

  • STOCH < 50: The STOCH %K is below 50. There are more sellers than buyers. -1
  • STOCH < 20: The STOCH %K is below 20 and oversold. -2
  • STOCH %K line < STOCH %D line: The STOCH %K line is below the STOCH %D line, which indicates a bearish signal in the market. This means that the negative momentum is currently stronger than the average momentum, suggesting that sellers are more active than buyers, and there's a higher probability of the Acadia price going down in the near term. -2
  • Trending up: The STOCH %K is trending up. +1
ACADIA Pharmaceuticals Inc Daily Stochastic Oscillator ChartACADIA Pharmaceuticals Inc Daily Stochastic Oscillator Chart
3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

  • Lagging or leading Momentum indicator
  • When the CCI is above zero, the price is above the historical average
  • When the CCI is below zero, the price is below the historical average
  • Used for spotting trends
    • If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
    • If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of ACADIA Pharmaceuticals Inc. The current cci is -159.59735107.

The long score for the Commodity Channel Index (CCI) is 0/1.
The longshort score for the Commodity Channel Index (CCI) is -1/(-1 +1).

  • CCI < -100: The CCI is below -100, it indicates that the price is significantly below its average, suggesting a potential oversold condition. -1
ACADIA Pharmaceuticals Inc Daily Commodity Channel Index (CCI) ChartACADIA Pharmaceuticals Inc Daily Commodity Channel Index (CCI) Chart
3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

  • Lagging momentum indicator
  • Ranges between +100 and -100
  • Considered overbought above +50
  • Considered oversold below -50
  • It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of ACADIA Pharmaceuticals Inc. The current cmo is -37.22775888.

The long score for the Chande Momentum Oscillator (CMO) is 0/1.
The longshort score for the Chande Momentum Oscillator (CMO) is -1/(-1 +1).

  • CMO < 0: The CMO is below 0, the momentum of the price is negative, indicating a potential downtrend in the price. -1
ACADIA Pharmaceuticals Inc Daily Chande Momentum Oscillator (CMO) ChartACADIA Pharmaceuticals Inc Daily Chande Momentum Oscillator (CMO) Chart
3.5 Williams %R

 Shows the current price relative to the highest high over the last 14 days.
 

  • Lagging momentum indicator
  • Ranging between 0 and -100
  • Above -20 is considered overbought
  • Below -80 is considered oversold
  • Is prone to give false signals

Score

Let's take a look at the Williams %R of ACADIA Pharmaceuticals Inc. The current willr is -95.41666667.

The long score for the Williams %R is 0/1.
The longshort score for the Williams %R is -1/(-1 +1).

  • WILLR < -80: The Williams %R is below -80. This indicates that the price is in oversold territory, suggesting a potential price correction or trend reversal to the upside. -1
ACADIA Pharmaceuticals Inc Daily Williams %R ChartACADIA Pharmaceuticals Inc Daily Williams %R Chart
3rd party ad coffee SUPPORTERis ad-free.

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

  • Lagging volatility indicator
  • Uses 3 bands: one upper, one lower and one in the middle
  • Works best when the middle band reflects an intermediate trend (MA20).
  • When the price is moving closer to the upper band, the market might be overbought
  • When the price is moving closer to the lower band, the market might be oversold 

Score

Let's take a look at the Bollinger Bands of ACADIA Pharmaceuticals Inc.

ACADIA Pharmaceuticals Inc Daily Bollinger Bands Chart
4.2 Average True Range (ATR)
Measures market volatility
  • Leading volatility indicator
  • Can be used to determine stop-loss positions
  • Calculated by:
    • Current high minus the current low
    • Current high minus the previous close
    • Current low minus the previous close
  • The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of ACADIA Pharmaceuticals Inc. The current atr is 0.82771201.

ACADIA Pharmaceuticals Inc Daily Average True Range (ATR) ChartACADIA Pharmaceuticals Inc Daily Average True Range (ATR) Chart
3rd party ad coffee SUPPORTERis ad-free.

5. Volume Indicators

5.1 On-Balance Volume (OBV)

 Measures market volatility

  • Leading momentum indicator
  • Calculation:
    • If the closing price is above the previous closing price: OBV = previous OBV + current volume
    • If the closing price is below the previous closing price: OBV = previous OBV - current volume
    • If the closing price is the same as the previous closing price than the OBV is the same.
  • Can be used to confirm price trends
  • Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of ACADIA Pharmaceuticals Inc. The current obv is -20,088,082.

ACADIA Pharmaceuticals Inc Daily On-Balance Volume (OBV) ChartACADIA Pharmaceuticals Inc Daily On-Balance Volume (OBV) Chart
5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

  • Lagging momentum indicator
  • Looks like RSI but uses volume as an extra metric (RSI only considers price)
  • Above 80 is considered overbought
  • Below 20 is considered oversold
  • Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of ACADIA Pharmaceuticals Inc. The current mfi is 48.64.

The long score for the Money Flow Index (MFI) is 0/2.
The longshort score for the Money Flow Index (MFI) is -1/(-2 +2).

  • MFI < 50: -1
ACADIA Pharmaceuticals Inc Daily Money Flow Index (MFI) ChartACADIA Pharmaceuticals Inc Daily Money Flow Index (MFI) Chart
3rd party ad coffee SUPPORTERis ad-free.

6. Summary

6.1. Notifications

TypeNotificationDate
PenkeCurrently no notifications for ACADIA Pharmaceuticals Inc.

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

DateIndicatorSignal
2025-02-11MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2025-02-12STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2025-02-13MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2025-02-18STOCH LONG EXITThe %K line crosses below the %D line.
2025-02-20STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2025-02-21STOCH LONG EXITThe %K line crosses below the %D line.
2025-02-25MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2025-02-27SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2025-03-03SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-03-04DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2025-03-06BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2025-03-07STOCH SHORT EXITThe %K line crosses above the %D line.
2025-03-10STOCH LONG EXITThe %K line crosses below the %D line.
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2025-03-11STOCH SHORT EXITThe %K line crosses above the %D line.
2025-03-12STOCH LONG EXITThe %K line crosses below the %D line.
2025-03-13STOCH SHORT EXITThe %K line crosses above the %D line.
MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2025-03-14MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2025-03-17WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-03-18STOCH LONG EXITThe %K line crosses below the %D line.
2025-03-19STOCH SHORT EXITThe %K line crosses above the %D line.
MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2025-03-20STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-03-24SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH SHORT EXITThe %K line crosses above the %D line.
2025-03-27MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2025-03-28STOCH LONG EXITThe %K line crosses below the %D line.
2025-03-31MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2025-04-01WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2025-04-02STOCH SHORT EXITThe %K line crosses above the %D line.
2025-04-03STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2025-04-04ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-04-07STOCH SHORT EXITThe %K line crosses above the %D line.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-04-08MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2025-04-09RSI LONG ENTRY SHORT CLOSE30 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2025-04-10STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-04-11RSI LONG ENTRY SHORT CLOSE30 crossover to upside
STOCH SHORT EXITThe %K line crosses above the %D line.
2025-04-15SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
2025-04-16STOCH LONG EXITThe %K line crosses below the %D line.
2025-04-17STOCH SHORT EXITThe %K line crosses above the %D line.
2025-04-21STOCH LONG EXITThe %K line crosses below the %D line.
2025-04-23MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
STOCH SHORT EXITThe %K line crosses above the %D line.
2025-04-29STOCH LONG EXITThe %K line crosses below the %D line.
2025-04-30STOCH SHORT EXITThe %K line crosses above the %D line.
2025-05-01STOCH LONG EXITThe %K line crosses below the %D line.
2025-05-02STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2025-05-05CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2025-05-06STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2025-05-08DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-05-12STOCH LONG EXITThe %K line crosses below the %D line.
2025-05-15STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2025-05-16STOCH LONG EXITThe %K line crosses below the %D line.
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-05-19MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2025-05-22MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2025-05-23STOCH SHORT EXITThe %K line crosses above the %D line.
2025-05-27MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2025-05-28STOCH LONG EXITThe %K line crosses below the %D line.
2025-05-30SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
RSI SHORT ENTRY LONG CLOSE70 crossover to downside
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2025-06-03STOCH SHORT EXITThe %K line crosses above the %D line.
2025-06-04MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
RSI SHORT ENTRY LONG CLOSE70 crossover to downside
2025-06-05STOCH LONG EXITThe %K line crosses below the %D line.
2025-06-09STOCH SHORT EXITThe %K line crosses above the %D line.
2025-06-10STOCH LONG EXITThe %K line crosses below the %D line.
2025-06-11STOCH SHORT EXITThe %K line crosses above the %D line.
2025-06-12STOCH LONG EXITThe %K line crosses below the %D line.
2025-06-16STOCH SHORT EXITThe %K line crosses above the %D line.
2025-06-17CCI LONG ENTRY SHORT CLOSE100 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2025-06-18WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2025-06-20SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH LONG EXITThe %K line crosses below the %D line.
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2025-06-24MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2025-06-25STOCH SHORT EXITThe %K line crosses above the %D line.
2025-06-26STOCH LONG EXITThe %K line crosses below the %D line.
2025-06-30CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-07-01SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2025-07-03BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.

6.3. Candlestick Patterns

ACADIA Pharmaceuticals Inc Daily Candlestick Chart
DateCandlestick Pattern

6.4. Technical Score

Let's check the technical score of ACADIA Pharmaceuticals Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5044.081
Ma 20Greater thanMa 5022.051
Ma 50Greater thanMa 10019.826
Ma 100Greater thanMa 20018.514
OpenGreater thanClose21.380
Total4/5 (80.0%)
Penke
Good job! You gained 25 XP and 0   0   10 . What's next:
  • Share my analysis of Acadia with someone you think should read this too:
  • Are you bullish or bearish on Acadia? Let me know what you think in the comments.
  • Do you want an email if I find something interesting about Acadia? Add an email alert using the form below.
  • Join the community if you want to keep your earnings and track your progress: Join the community
  • Is this analysis useful to you? Support me via But Me a Coffee. I'll analyze the stock market faster for you!

Get notifications about ACADIA Pharmaceuticals Inc

I send you an email if I find something interesting about ACADIA Pharmaceuticals Inc.


Comments

How you think about this?

Leave a comment

Stay informed about ACADIA Pharmaceuticals Inc.

Receive notifications about ACADIA Pharmaceuticals Inc in your mailbox!

3rd party ad coffee SUPPORTERis ad-free.